ecNOS overexpression in CsA-treated renal transplant patients:: Implications for CsA-induced hypertension

被引：10
|
作者：
Colò, L
Davis, PA
Rigotti, P
Milani, M
Cantaro, S
Marchini, F
D'Angelo, A
Antonello, A
机构：
[1] Univ Padua, Inst Internal Med, Div Nephrol, I-35128 Padua, Italy
[2] Univ Padua, Div Gen Surg 2, Inst Internal Med, Padua, Italy
[3] Univ Calif Davis, Dept Internal Med, Davis, CA USA
来源：
TRANSPLANTATION PROCEEDINGS | 1998年 / 30卷 / 05期
关键词：
D O I：
10.1016/S0041-1345(98)00514-4
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
下载
收藏
页码：2012 / 2013
页数：2
相关论文
共 50 条
  • [31] Rapamycin (RAPA) lowers dose requirements of cyclosporin (CsA) in renal transplant patients (RTx)
    Ahuja, M
    Jaffe, JS
    Bresnahan, B
    Adams, MB
    Johnson, CP
    Roza, AM
    Hariharan, S
    TRANSPLANTATION, 1999, 67 (07) : S167 - S167
  • [32] MONITORING OF T-CELL SUBSETS IN RENAL-TRANSPLANT RECIPIENTS TREATED WITH CYCLOSPORIN-A (CSA)
    HALL, BM
    BISHOP, GA
    WAUGH, J
    TILLER, DJ
    HORVATH, JS
    DUGGIN, GG
    SHEIL, AGR
    KIDNEY INTERNATIONAL, 1984, 26 (02) : 237 - 237
  • [33] Osteonecrosis of the femoral heads (OFH) in renal transplant patients (RTP) in the cyclosporine (CsA) era.
    Pabico, RC
    Rosier, R
    OKeefe, R
    McKenna, B
    Totterman, S
    Orloff, M
    Erturk, E
    Yarger, J
    Byer, B
    Kremer, M
    Monaghan, J
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1997, 8 : A3337 - A3337
  • [34] Selective impairment of endothelium-mediated vasodilation in liver transplant (LT) patients with cyclosporin A (CsA)-induced arterial hypertension (AH).
    Cacho, G
    Albillos, A
    Barrios, C
    Paramo, MP
    Rossi, I
    Calleja, JL
    Munoz, J
    AlvarezMon, M
    Cuervas, V
    Escartin, P
    HEPATOLOGY, 1997, 26 (04) : 864 - 864
  • [35] Single and multiple-dose pharmacokinetics of a new HMG-COA reductase inhibitor in renal transplant patients treated with cyclosporine A (CSA)
    Mai, I
    Bauer, S
    Johne, A
    Fritsche, L
    Ochmann, K
    Mück, W
    Rohde, G
    Roots, I
    Neumayer, HH
    Kuhlmann, J
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1998, 358 (01) : R465 - R465
  • [36] EFFECT OF NIFEDIPINE, PROPRANOLOL AND OTHER ANTIHYPERTENSIVE DRUGS ON RENAL-FUNCTION OF TRANSPLANT RECIPIENTS TREATED WITH CYCLOSPORINE (CSA)
    SOLEZ, K
    RACUSEN, LC
    VAUGHN, WK
    KIDNEY INTERNATIONAL, 1988, 33 (01) : 367 - 367
  • [37] COMPARISON OF CYCLOSPORINE (CSA) BLOOD-LEVELS AND RIA HPLC RATIOS AMONG RENAL-TRANSPLANT PATIENTS WITH NORMAL ALLOGRAFT FUNCTION, CSA NEPHROTOXICITY OR REJECTION
    VEREMIS, SA
    MADDUX, MS
    TANG, IYS
    MILLNER, SN
    PRASAD, R
    POLLAK, R
    MOZES, MF
    TRANSPLANTATION PROCEEDINGS, 1989, 21 (01) : 1476 - 1477
  • [38] EFFECTS OF THE PROSTACYCLIN-ANALOG ILOPROST ON CYCLOSPORINE (CSA)-INDUCED RENAL HYPOPERFUSION IN STABLE RENAL-TRANSPLANT RECIPIENTS
    HANSEN, JM
    CHRISTENSEN, NJ
    FOGHANDERSEN, N
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1995, 6 (03): : 998 - 998
  • [39] ORAL MAGNESIUM (MG++) REPLETION IN RENAL-TRANSPLANT PATIENTS (RTPS) TAKING CYCLOSPORINE (CSA)
    NGUYEN, T
    ZIEGLER, M
    STEINER, R
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1995, 6 (03): : 1108 - 1108
  • [40] DISADVANTAGES AND ADVANTAGES OF IMMUNOSUPPRESSIVE THERAPY WITH CSA IN RENAL-TRANSPLANT PATIENTS ON THE BASIS OF 5 YEARS EXPERIENCE
    KONIG, P
    SPIELBERGER, M
    KATHREIN, H
    LECHLEITNER, P
    LECHLEITNER, M
    MARGREITER, R
    ACTA MEDICA AUSTRIACA, 1985, 12 : 38 - 39
12345